Skip to main content
Premium Trial:

Request an Annual Quote

OGS Inks Second Deal with Pfizer

NEW YORK, Jan. 7-Oxford GlycoSciences said today that it has expanded its proteomics contract with Pfizer.

 

OGS first struck a deal with Pfizer in 1998, a collaboration intended to identify new biomarkers and drug targets in Alzheimer's disease, arteriosclerosis and other diseases.

 

The disease area and financial terms of the new agreement were not disclosed.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more